Immune suppression in head and neck cancers: a review

Clin Dev Immunol. 2010:2010:701657. doi: 10.1155/2010/701657. Epub 2011 Mar 10.

Abstract

Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common cancer in the world. Despite significant advances in the treatment modalities involving surgery, radiotherapy, and concomitant chemoradiotherapy, the 5-year survival rate remained below 50% for the past 30 years. The worse prognosis of these cancers must certainly be link to the fact that HNSCCs strongly influence the host immune system. We present a critical review of our understanding of the HNSCC escape to the antitumor immune response such as a downregulation of HLA class I and/or components of APM. Antitumor responses of HNSCC patients are compromised in the presence of functional defects or apoptosis of T-cells, both circulating and tumor-infiltrating. Langerhans cells are increased in the first steps of the carcinogenesis but decreased in invasive carcinomas. The accumulation of macrophages in the peritumoral areas seems to play a protumoral role by secreting VEGF and stimulating the neoangiogenesis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Apoptosis
  • Carcinoma, Squamous Cell / epidemiology
  • Carcinoma, Squamous Cell / immunology*
  • Carcinoma, Squamous Cell / physiopathology
  • HLA Antigens / genetics
  • HLA Antigens / metabolism
  • Head and Neck Neoplasms / epidemiology
  • Head and Neck Neoplasms / immunology*
  • Head and Neck Neoplasms / physiopathology
  • Humans
  • Immunosuppression Therapy
  • Macrophages / immunology
  • Neovascularization, Pathologic
  • T-Lymphocytes / immunology
  • Tumor Escape*
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • HLA Antigens
  • Vascular Endothelial Growth Factor A